A clinical trial demonstrated that a single intramuscular dose of benzathine penicillin G is as effective as three weekly doses for treating early syphilis, achieving a serologic response in 76% of patients within six months. Conducted across 10 US sites from October 2018 to March 2022, the study involved 249 participants, predominantly men and a significant proportion living with HIV. Results indicated no clinical relapses and highlighted the benefits of reduced treatment frequency and costs while ensuring effective management of the disease.

Source: The New England Journal of Medicine